Le Lézard
Classified in: Health, Science and technology, Business
Subject: ERN

Immunovia Interim Report, January-March 2019


STOCKHOLM, April 24, 2019 /PRNewswire/ -- During the first quarter of 2019, we remained focused on our product launch strategy and continued to create value, as we reached several key objectives and took several steps towards the commercialization of IMMraytm PanCan-d, our diagnostic test for early detection of pancreatic cancer.

Another key objective that we reached in the first quarter was the addition of new participants to our PanFAM-1 study, a multicenter prospective validation study for early diagnosis of people with a high risk of hereditary pancreatic cancer. In Q1 2019 we added two additional centers, one in Sweden and one in Spain. Umeå University Hospital in Sweden and Catalan Institute of Oncology (ICO Hospitalet) ? Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona are now part of PanFAM-1 study.

We also took an extremely important step towards on the optimization of the algorithm during Q1. We announced in March that using blood samples that are as fresh as possible, i.e. stored for less than 24 months, increases the test performance and provides optimal results. We were able to attain the relevant samples through our large and growing network of clinical Key Opinion Leaders (KOL). It is imperative to note that we needed samples that best mirror the blood samples that will be used with our final product, finding these fresh samples and gaining access to them is quite difficult and takes time.

With the appointment of Julie Silber as Senior Investor Relations Director early this year we actualized a strategic objective in strengthening the IR role and our shareholder communication capabilities at Immunovia.

We continued to work intensely during the first quarter of 2019 on the preparations for our sales launch targeted for the beginning of 2020.

Excerpt from the CEO Mats Grahn's comment on the report.

Key Indicators

 

 

Key Indicators (SEK thousand unless otherwise stated)

 

Jan-Mar 2019

 

Jan-Mar 2018

 

Full year 2018

 

 

Full year 2017

 

Net Sales

 

66

 

112

 

333

 

149

 

 

Operating earnings

 

-27,197

 

-17,377

 

-87,708

 

-45,520

 

 

Earnings before tax

 

-26,381

 

-17,326

 

-86,531

 

-45,323

 

 

Net earnings

 

-26,384

 

-17,326

 

-86,536

 

-45,232

 

 

Earnings per share before and after dilution (SEK/share)

 

-1.35

 

-1.00

 

-4.67

 

-2.67

 

 

Equity ratio, %

 

89

 

94

 

97

 

94

 

 

No. of shares at the end of the period

 

19,531,353

 

17,318,059

 

19,531,353

 

17,318,059

 

 

This financial statement has been produced in accordance with IFRS for the Immunovia Group, which comprises Immunovia AB and the wholly-owned subsidiaries Immunovia Incentive AB, Immunovia Inc. and Immunovia GmbH.

Outlook
Immunovia is focused on fundamentally transforming diagnosis of complex forms of cancer and autoimmune diseases. The antibody-based platform, IMMraytm, is the result of 15 years of research at CREATE Health ? the Center for Translational Cancer Research at Lund University, Sweden. IMMraytm is a technology platform for the development of diagnostic tests and the company's primary test, IMMraytm PanCan?d, is the first test in the world for early diagnosis of pancreatic cancer.

The Company reiterates it's financial targets in accordance with what has previously been disclosed. The company anticipates the first revenues from self pay sales in early 2020.The following financial targets have been established:

Immunovia invites to a teleconference (in English) for investors, analysts and media on Monday April 29, at 3:00 ? 4:00 p.m. CET

Mats Grahn, CEO will present Immunovia and comment on the interim report for the period January-March 2019, give an update from the Annual General Meeting on April 26, followed by a Q&A session. Please call in a few minutes in advance.

To attend, please dial-in at one of the numbers below:

BE: +3226200547 
DK: +4578150110 
FR: +33170750775
DE: +496913803452 
NO: +4723500236 
SE: +46856642695 
CH: +41225675632 
NL: +31207219495 
UK: +443333009274 
US: +18335268383

For questions or interview bookings:
ir@immunovia.com 

There will be an MP3-file available at Immunovia's webpage under Investors/Financial Reports (http://immunovia.com/investors/financial-reports/) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.

For more information, please contact:
Julie Silber
Director of Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46 7 93 486 277

About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMraytm, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMraytm PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com)

This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia-interim-report--january-march-2019,c2795278

The following files are available for download:

https://mb.cision.com/Main/13121/2795278/1030635.pdf

Press Release

 

SOURCE Immunovia AB


These press releases may also interest you

at 18:10
Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced that an abstract describing clinical data regarding their lysine-specific demethylase (LSD1)...

at 18:08
This report provides forecast and analysis of the global medical nutrition market.It provides estimated data of 2018, and forecast data up to 2027 in terms of revenue (US$ Mn) and volume (metric tons).Read the full report:...

at 18:08
About this marketThe increasing number of cervical cancer endoscopic device launches is one of the key factors that will trigger the market growth during the forecast period. With the rising prevalence of cervical cancer, manufacturers are focusing...

at 18:08
Global Negative-pressure Wound Therapy Devices Market: OverviewThe global negative-pressure wound therapy devices market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of...

at 18:00
The 17th annual FedEx/St. Jude Angels and Stars Gala benefiting St. Jude Children's Research Hospital® united philanthropists, influencers and celebrities who raised $800,000 for the fight to end childhood cancer on Saturday, May 18, at the...

at 18:00
The "Oman Fitness Services Market Outlook to 2022 - By Gym Membership and Personal Training, by Region, by Gender and by Membership Subscription" report has been added to ResearchAndMarkets.com's offering. Oman fitness services market has witnessed a...



News published on 24 april 2019 at 04:33 and distributed by: